Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Payables (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Payables for 14 consecutive years, with $40.4 million as the latest value for Q4 2025.

  • Quarterly Payables rose 163.03% to $40.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.4 million through Dec 2025, up 163.03% year-over-year, with the annual reading at $40.4 million for FY2025, 163.03% up from the prior year.
  • Payables hit $40.4 million in Q4 2025 for Corcept Therapeutics, up from $34.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $40.4 million in Q4 2025 to a low of $6.6 million in Q3 2021.
  • Historically, Payables has averaged $15.6 million across 5 years, with a median of $12.3 million in 2022.
  • Biggest five-year swings in Payables: crashed 34.55% in 2021 and later surged 163.03% in 2025.
  • Year by year, Payables stood at $6.9 million in 2021, then surged by 73.36% to $12.0 million in 2022, then skyrocketed by 45.26% to $17.4 million in 2023, then fell by 11.61% to $15.4 million in 2024, then surged by 163.03% to $40.4 million in 2025.
  • Business Quant data shows Payables for CORT at $40.4 million in Q4 2025, $34.4 million in Q3 2025, and $23.5 million in Q2 2025.